A glimpse into the future of systemic lupus erythematosus

• Published in: Therapeutic Advances in Musculoskeletal Disease Vol. 14; p. 1759720X221086719
• Main Authors: Aringer, Martin, Alarcón-Riquelme, Marta E., Clowse, Megan, Pons-Estel, Guillermo J., Vital, Edward M., Dall’Era, Maria
• Format: Book Review Journal Article
• Language: English
• Published: London, England SAGE Publications 01.03.2022; SAGE PUBLICATIONS, INC; SAGE Publishing
• Subjects: A Glance into the Future of Rheumatology; Lupus; Medical diagnosis; Monoclonal antibodies; Musculoskeletal diseases; systemic lupus erythematosus; therapy; calcineurin inhibition; interferon receptor blockade; diagnosis; lupus nephritis; B cell depletion; classification criteria; costimulation blockade; quality of life; recommendations
• ISSN: 1759-720X; 1759-7218
• DOI: 10.1177/1759720X221086719

This viewpoint article on a forecast of clinically meaningful changes in the management of systemic lupus erythematosus (SLE) in the next 10 years is based on a review of the current state of the art. The groundwork has been laid by a robust series of classification criteria and treatment recommendations that have all been published since 2019. Building on this strong foundation, SLE management predictably will take significant steps forward. Assessment for lupus arthritis will presumably include musculoskeletal sonography. Large-scale polyomics studies are likely to unravel more of the central immune mechanisms of the disease. Biomarkers predictive of therapeutic success may enter the field; the type I interferon signature, as a companion for use of anifrolumab, an antibody against the common type I interferon receptor, is one serious candidate. Besides anifrolumab for nonrenal SLE and the new calcineurin inhibitor voclosporin in lupus nephritis, both of which are already approved in the United States and likely to become available in the European Union in 2022, several other approaches are in advanced clinical trials. These include advanced B cell depletion, inhibition of costimulation via CD40 and CD40 ligand (CD40L), and Janus kinase 1 (Jak1) and Tyrosine kinase 2 (Tyk2) inhibition. At the same time, essentially all of our conventional therapeutic armamentarium will continue to be used. The ability of patients to have successful SLE pregnancies, which has become much better in the last decades, should further improve, with approaches including tumor necrosis factor blockade and self-monitoring of fetal heart rates. While we hope that the COVID-19 pandemic will soon be controlled, it has highlighted the risk of severe viral infections in SLE, with increased risk tied to certain therapies. Although there are some data that a cure might be achievable, this likely will remain a challenge beyond 10 years from now.